Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12943-019-1073-4.

Title:
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression | Molecular Cancer
Description:
Background The ATLANTIC trial reported that higher PD-L1 expression in tumors was involved in a higher objective response in patients with EGFR+/ALK+ non-small cell lung cancer (NSCLC), indicating the possibility of anti-PD-1/PD-L1 therapy as a third-line (or later) treatment for advanced NSCLC. Therefore, the determination of status and regulatory mechanisms of PD-L1 in EGFR mutant NSCLC before and after acquired EGFR-TKIs resistance are meaningful. Methods The correlation among PD-L1, c-MET, and HGF was analyzed based on TCGA datasheets and paired NSCLC specimens before and after acquired EGFR-TKI resistance. EGFR-TKI resistant NSCLC cells with three well-known mechanisms, c-MET amplification, hepatocyte growth factor (HGF), and EGFR-T790M, were investigated to determinate PD-L1 expression status and immune escape ability. PD-L1-deleted EGFR-TKIs sensitive and resistant cells were used to evaluate the immune escape ability of tumors in mice xenograft models. Results Positive correlations were found among PD-L1, c-MET, and HGF, based on TCGA datasheets and paired NSCLC specimens. Moreover, the above three resistant mechanisms increased PD-L1 expression and attenuated activation and cytotoxicity of lymphocytes in vitro and in vivo, and downregulation of PD-L1 partially restored the cytotoxicity of lymphocytes. Both MAPK and PI3K pathways were involved in the three types of resistance mechanism-induced PD-L1 overexpression, whereas the NF-kappa B pathway was only involved in T790M-induced PD-L1 expression. Conclusions HGF, MET-amplification, and EGFR-T790M upregulate PD-L1 expression in NSCLC and promote the immune escape of tumor cells through different mechanisms.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Science
  • Education
  • Health & Fitness

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We can't figure out the monetization strategy.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {šŸ”}

pdl, cells, expression, nsclc, cancer, egfrtki, resistant, pubmed, lung, cmet, article, egfr, resistance, google, scholar, hgf, patients, cell, cas, immune, figure, egfrtkis, pcr, additional, fig, treatment, pathway, mutant, amplification, mapk, tumour, file, mutation, wang, mechanisms, signaling, results, activation, gefitinib, acquired, growth, pathways, nfkappa, tumours, human, lymphocytes, percentage, pikakt, escape, involved,

Topics {āœ’ļø}

pd-l1-deleted egfr-tkis sensitive egfr-tkiĀ resistant lung cancer pd-1/pd-l1 axis plays pd-1/pd-l1 therapies require c-met amplification-induced upregulation c-met si-rnas downregulate anti-pd-1/pd-l1 inhibitors pd-l1-induced primary resistance anti-pd-l1 antibodies restores anti-pd-1/pd-l1 therapies t790m-induced pd-l1 expression hgf-mediated pd-l1 expression egfr-tkiĀ resistant mechanisms related egfr-tkiĀ resistant nsclc cells egfr-related pd-l1 expression hgf-induced pd-l1 upregulation pd-1/pd-l1 immune checkpoint anti-pd-l1 monoclonal antibody hgf-induced pd-l1 expression anti-pd-1/pd-l1 therapy egfr-tkisĀ resistant nsclc tumours egfr+/c-met+ mutant nsclc egfr+/c-metāˆ’ mutant nsclc crispr-cas9 knockout lentiviruses anti-pd-l1 antibodies restored egfr-tkisĀ resistant nsclc cells pi3k/akt/nf-kappab signaling pathway pc-9rpd-l1- tumours responded small-cell lung cancer crispr-cas9 knockout lentivirus cd3āˆ’cd16+cd56+ nk cells egfr-tki resistant nsclc egfr-tkiĀ resistant nsclc pd-1/pd-l1 inhibitors acquiring egfr-tki resistance generated egfr-tki sensitive pd-l1 expression induced dual pi3k/mtor inhibitors pc-9r pd-l1- xenografts c-jun si-rna generation egfr-tkisĀ resistance [10] egfr-tkis resistant nsclc egfr-tkisĀ resistant nsclc upregulate pd-l1 expression members including c-jun c-met sirna combined pc-9rpd-l1- tumours shows induce egfr-tkis resistance acquiredĀ egfr-tki resistance acquired egfr-tki resistance

Questions {ā“}

  • ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
  • Does c-met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
  • What does PD-L1 positive or negative mean?
  • Org/study?

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
         description:The ATLANTIC trial reported that higher PD-L1 expression in tumors was involved in a higher objective response in patients with EGFR+/ALK+ non-small cell lung cancer (NSCLC), indicating the possibility of anti-PD-1/PD-L1 therapy as a third-line (or later) treatment for advanced NSCLC. Therefore, the determination of status and regulatory mechanisms of PD-L1 in EGFR mutant NSCLC before and after acquired EGFR-TKIs resistance are meaningful. The correlation amongĀ PD-L1, c-MET, and HGF was analyzed based on TCGA datasheets and paired NSCLC specimens before and after acquiredĀ EGFR-TKI resistance. EGFR-TKI resistant NSCLC cells with three well-known mechanisms, c-MET amplification, hepatocyte growth factor (HGF), and EGFR-T790M, were investigated to determinate PD-L1 expression status and immune escape ability. PD-L1-deleted EGFR-TKIs sensitive and resistant cells were used to evaluate the immune escape ability of tumors in mice xenograft models. Positive correlations were found amongĀ PD-L1, c-MET, and HGF, based on TCGA datasheets and paired NSCLC specimens. Moreover, the above three resistant mechanisms increased PD-L1 expression and attenuated activation and cytotoxicity of lymphocytes in vitro and in vivo, and downregulation of PD-L1 partially restored the cytotoxicity of lymphocytes. Both MAPK and PI3K pathways were involved in the three types of resistance mechanism-induced PD-L1 overexpression, whereas the NF-kappa B pathway was only involved in T790M-induced PD-L1 expression. HGF, MET-amplification, and EGFR-T790M upregulate PD-L1 expression in NSCLC and promote the immune escape of tumor cells through different mechanisms.
         datePublished:2019-11-20T00:00:00Z
         dateModified:2019-11-20T00:00:00Z
         pageStart:1
         pageEnd:14
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12943-019-1073-4
         keywords:
            PD-L1
            EGFR-TKIs resistance
            Signaling pathways
            Lung cancer
            Immunotherapy
            Cancer Research
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig6_HTML.png
         isPartOf:
            name:Molecular Cancer
            issn:
               1476-4598
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Shunli Peng
               affiliation:
                     name:Nanfang Hospital, Southern Medical University
                     address:
                        name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rong Wang
               affiliation:
                     name:Nanfang Hospital, Southern Medical University
                     address:
                        name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaojuan Zhang
               affiliation:
                     name:Nanfang Hospital, Southern Medical University
                     address:
                        name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yueyun Ma
               affiliation:
                     name:Nanfang Hospital, Southern Medical University
                     address:
                        name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Longhui Zhong
               affiliation:
                     name:Nanfang Hospital, Southern Medical University
                     address:
                        name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ke Li
               affiliation:
                     name:Nanfang Hospital, Southern Medical University
                     address:
                        name:Center for Clinical Medicine Research, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Akihiro Nishiyama
               affiliation:
                     name:Cancer Research Institute, Kanazawa University
                     address:
                        name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sachiko Arai
               affiliation:
                     name:Cancer Research Institute, Kanazawa University
                     address:
                        name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Seiji Yano
               affiliation:
                     name:Cancer Research Institute, Kanazawa University
                     address:
                        name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Wei Wang
               affiliation:
                     name:Nanfang Hospital, Southern Medical University
                     address:
                        name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
      description:The ATLANTIC trial reported that higher PD-L1 expression in tumors was involved in a higher objective response in patients with EGFR+/ALK+ non-small cell lung cancer (NSCLC), indicating the possibility of anti-PD-1/PD-L1 therapy as a third-line (or later) treatment for advanced NSCLC. Therefore, the determination of status and regulatory mechanisms of PD-L1 in EGFR mutant NSCLC before and after acquired EGFR-TKIs resistance are meaningful. The correlation amongĀ PD-L1, c-MET, and HGF was analyzed based on TCGA datasheets and paired NSCLC specimens before and after acquiredĀ EGFR-TKI resistance. EGFR-TKI resistant NSCLC cells with three well-known mechanisms, c-MET amplification, hepatocyte growth factor (HGF), and EGFR-T790M, were investigated to determinate PD-L1 expression status and immune escape ability. PD-L1-deleted EGFR-TKIs sensitive and resistant cells were used to evaluate the immune escape ability of tumors in mice xenograft models. Positive correlations were found amongĀ PD-L1, c-MET, and HGF, based on TCGA datasheets and paired NSCLC specimens. Moreover, the above three resistant mechanisms increased PD-L1 expression and attenuated activation and cytotoxicity of lymphocytes in vitro and in vivo, and downregulation of PD-L1 partially restored the cytotoxicity of lymphocytes. Both MAPK and PI3K pathways were involved in the three types of resistance mechanism-induced PD-L1 overexpression, whereas the NF-kappa B pathway was only involved in T790M-induced PD-L1 expression. HGF, MET-amplification, and EGFR-T790M upregulate PD-L1 expression in NSCLC and promote the immune escape of tumor cells through different mechanisms.
      datePublished:2019-11-20T00:00:00Z
      dateModified:2019-11-20T00:00:00Z
      pageStart:1
      pageEnd:14
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12943-019-1073-4
      keywords:
         PD-L1
         EGFR-TKIs resistance
         Signaling pathways
         Lung cancer
         Immunotherapy
         Cancer Research
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-019-1073-4/MediaObjects/12943_2019_1073_Fig6_HTML.png
      isPartOf:
         name:Molecular Cancer
         issn:
            1476-4598
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Shunli Peng
            affiliation:
                  name:Nanfang Hospital, Southern Medical University
                  address:
                     name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rong Wang
            affiliation:
                  name:Nanfang Hospital, Southern Medical University
                  address:
                     name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaojuan Zhang
            affiliation:
                  name:Nanfang Hospital, Southern Medical University
                  address:
                     name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yueyun Ma
            affiliation:
                  name:Nanfang Hospital, Southern Medical University
                  address:
                     name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Longhui Zhong
            affiliation:
                  name:Nanfang Hospital, Southern Medical University
                  address:
                     name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ke Li
            affiliation:
                  name:Nanfang Hospital, Southern Medical University
                  address:
                     name:Center for Clinical Medicine Research, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Akihiro Nishiyama
            affiliation:
                  name:Cancer Research Institute, Kanazawa University
                  address:
                     name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sachiko Arai
            affiliation:
                  name:Cancer Research Institute, Kanazawa University
                  address:
                     name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Seiji Yano
            affiliation:
                  name:Cancer Research Institute, Kanazawa University
                  address:
                     name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Wei Wang
            affiliation:
                  name:Nanfang Hospital, Southern Medical University
                  address:
                     name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Molecular Cancer
      issn:
         1476-4598
      volumeNumber:18
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Nanfang Hospital, Southern Medical University
      address:
         name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
         type:PostalAddress
      name:Nanfang Hospital, Southern Medical University
      address:
         name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
         type:PostalAddress
      name:Nanfang Hospital, Southern Medical University
      address:
         name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
         type:PostalAddress
      name:Nanfang Hospital, Southern Medical University
      address:
         name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
         type:PostalAddress
      name:Nanfang Hospital, Southern Medical University
      address:
         name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
         type:PostalAddress
      name:Nanfang Hospital, Southern Medical University
      address:
         name:Center for Clinical Medicine Research, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
         type:PostalAddress
      name:Cancer Research Institute, Kanazawa University
      address:
         name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
         type:PostalAddress
      name:Cancer Research Institute, Kanazawa University
      address:
         name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
         type:PostalAddress
      name:Cancer Research Institute, Kanazawa University
      address:
         name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
         type:PostalAddress
      name:Nanfang Hospital, Southern Medical University
      address:
         name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Shunli Peng
      affiliation:
            name:Nanfang Hospital, Southern Medical University
            address:
               name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Rong Wang
      affiliation:
            name:Nanfang Hospital, Southern Medical University
            address:
               name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Xiaojuan Zhang
      affiliation:
            name:Nanfang Hospital, Southern Medical University
            address:
               name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Yueyun Ma
      affiliation:
            name:Nanfang Hospital, Southern Medical University
            address:
               name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Longhui Zhong
      affiliation:
            name:Nanfang Hospital, Southern Medical University
            address:
               name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Ke Li
      affiliation:
            name:Nanfang Hospital, Southern Medical University
            address:
               name:Center for Clinical Medicine Research, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Akihiro Nishiyama
      affiliation:
            name:Cancer Research Institute, Kanazawa University
            address:
               name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
               type:PostalAddress
            type:Organization
      name:Sachiko Arai
      affiliation:
            name:Cancer Research Institute, Kanazawa University
            address:
               name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
               type:PostalAddress
            type:Organization
      name:Seiji Yano
      affiliation:
            name:Cancer Research Institute, Kanazawa University
            address:
               name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Wei Wang
      affiliation:
            name:Nanfang Hospital, Southern Medical University
            address:
               name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
      name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
      name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
      name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
      name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
      name:Center for Clinical Medicine Research, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
      name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
      name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
      name:Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
      name:Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China

External Links {šŸ”—}(196)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

6.58s.